The global leukapheresis market was valued at 61.2 million in 2020 and is expected to grow at a CAGR of 8.3% during the forecast period. This industry growth is attributed to the increasing prevalence of leukemia, increasing demand for leukopaks with a high concentration of leukocytes, and its rising application in research activities.
Moreover, the ongoing COVID-19 pandemic has impacted the industry positively as several studies are being conducted on White Blood Cells (WBC). For instance, NIH is carrying out clinical trials that require leukapheresis to understand the effect of coronavirus on lymphocytes. Such initiatives by the government in the pandemic have contributed significantly towards the leukapheresis industry growth.
Know more about this report: request for sample pages
Increasing incidence and prevalence of leukemia is one of the significant factors contributing towards the industry growth. For instance, according to the data published in leukemia and lymphoma society, an estimated 178,520 people in the U.S. were diagnosed with leukemia and lymphoma, in 2020, with new cases that account for 9.9% in the same year.
Moreover, researchers are researching pediatrics for applying leukapheresis, which will further fuel the industry scope over the forecast period. However, huge costs of therapeutic leukapheresis and leukopaks and the strict government legislations for leukocyte donor is limiting the industry growth to some extent.
The market is primarily segmented on the basis of type, application, end-use, and region.
Know more about this report: request for sample pages
Based on the type, the industry is classified into leukapheresis devices and leukapheresis disposables. Of all, the leukapheresis device segment held the largest share in the global market. In 2020, the increasing adoption of therapeutic leukapheresis procedures and devices used for leukemia treatment was driving the market growth of this segment. The growing adoption of and rising blood collection centers using these devices is another major factor supporting industry growth.
Furthermore, the rising number of product launches and mergers & acquisitions by the players in the market is propelling the market growth. For instance, in May 2019, JCRC company innovated an apheresis machine that helps in cell collection and is being used in the country, such as Uganda. The device uses optical detection technology and innovations in the concerned sector, increasing the segment’s growth prospects.
On the basis of application, the global market is categorized into research and therapeutic areas. The research application is expected to witness the highest CAGR during the forecast period, owing to an increasing number of research activities focused on leukapheresis and increasing healthcare spending by the government. For instance, research studies are being conducted to hypothesize. Chimeric antigen receptor (CAR) T cell therapy may be offered to people with cancer. Moreover, leukapheresis is considered the first step in such treatment.
The leukapheresis market is categorized into blood centers, research institutes, pharmaceutical and biotechnology companies, hospitals, and transfusion centers based on application. The blood center is anticipated to register the highest growth over the study period, owing to various factors such as the increasing number of blood donations and the increasing research studies focused on using these cells to treat diseases such as cancer.
North America dominated the leukapheresis market due to various factors such as well-established healthcare infrastructure, the increasing patient population suffering from leukemia, and a rising number of R&D activities in this region. In addition, focus on improving patients suffering from cancer by using CAR T cells coupled with well-established significant players in the market involved in new product launches, strategic collaborations, mergers & acquisitions, and expansions is likely to complement market growth.
For instance, considering the rising burden of leukemia in this region, according to the American Cancer Society, 60,530 new cases of all types of leukemia resulted in 23,100 deaths in 2020. Acute myeloid leukemia (AML) is the most prevalent type of leukemia that led to 19,940 cases in the U.S. Therefore, this rising burden of the disease in this region demands an effective treatment such as leukapheresis, and in turn, these aids to augment the market growth.
The Asia Pacific is expected to exhibit the fastest-growing region. This region's market growth can be attributed to the increase in clinical trials focused on CAR-T cell therapy and the rapidly increasing pool of patient populations suffering from leukemia and other cancer types. These factors are promoting the market growth of leukapheresis in this region.
Few of the key players operating in the global market include AllCells, LLC, StemExpress, LLC., Haemonetics Corporation, Caltag Medsystems Limited, Lonza Group AG, ZenBio, Asahi Kasei Medical, Terumo BCT, Inc., Macopharma SA, Miltenyi Biotec, Fresenius SE & Co. KGaA, Guangzhou Daji Medical Science, MEDICA S.p.A, PuriBlood Medical Co. Ltd., and Beijing ZKSK Technology Co. Ltd.
Market size value in 2020
USD 61.2 million
Revenue forecast in 2028
USD 106.2 million
8.3% from 2021 - 2028
2016 - 2019
2021 - 2028
Revenue in USD million and CAGR from 2021 to 2028
By Type, By Application, By End-Use, By Region
North America, Europe, Asia Pacific, Latin America, Middle East & Africa
AllCells, LLC, StemExpress, LLC., Haemonetics Corporation, Caltag Medsystems Limited, Lonza Group AG, ZenBio, Asahi Kasei Medical, Terumo BCT, Inc., Macopharma SA, Miltenyi Biotec, Fresenius SE & Co. KGaA, Guangzhou Daji Medical Science, MEDICA S.p.A, PuriBlood Medical Co. Ltd., and Beijing ZKSK Technology Co. Ltd.